Anixa Biosciences (ANIX) Stock Price, News & Analysis

Company Overview

Anixa Biosciences, Inc. is a clinical-stage biotechnology company focused on developing immunotherapies and vaccines for cancer and infectious diseases. Rather than marketing a broad portfolio of commercial products, the company concentrates on advancing novel therapies through research collaborations and clinical development.

Anixa’s cancer programs include a breast cancer vaccine intended to target alpha-lactalbumin, a protein associated with certain breast cancers. The program is being developed in collaboration with researchers at Cleveland Clinic. The company has also pursued an ovarian cancer vaccine program and cellular immunotherapy approaches, including chimeric antigen receptor T-cell (CAR-T) technologies designed to improve the treatment of solid tumors.

The company’s activities are primarily centered in the United States and are conducted through partnerships with academic and medical research institutions. Anixa was previously known as ITUS Corporation before adopting its current name. Amit Kumar, Ph.D., serves as chairman and chief executive officer.

Key Stats

• Today's Range: $2.86 to $2.96
• 50-Day Range: $2.60 to $3.71
• 52-Week Range: $2.32 to $5.46
• Volume: 217,874 shs
• Average Volume: 356,134 shs
• Market Capitalization: $100.80 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.00
• Consensus Rating: Hold

Anixa Biosciences Stock Analysis - MarketRank™

Anixa Biosciences scored higher than 65% of companies evaluated by MarketBeat, and ranked 183rd out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Hold

Consensus Rating

Anixa Biosciences has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Anixa Biosciences has a consensus price target of $8.00, representing about 175.9% upside from its current price of $2.90.

Amount of Analyst Coverage

Anixa Biosciences has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Earnings Growth

Earnings for Anixa Biosciences are expected to remain at ($0.31) per share in the coming year.

Price to Earnings Ratio vs. the Market

The P/E ratio of Anixa Biosciences is -9.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Anixa Biosciences is -9.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Anixa Biosciences has a P/B Ratio of 6.90. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.28% of the float of Anixa Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Anixa Biosciences has a short interest ratio ("days to cover") of 3.69, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Anixa Biosciences has recently increased by 27.99%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Anixa Biosciences does not currently pay a dividend.

Dividend Growth

Anixa Biosciences does not have a long track record of dividend growth.

News and Social Media

• Score: 1.6 / 5
• News Sentiment: -0.43

News Sentiment

Anixa Biosciences has a news sentiment score of -0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Anixa Biosciences this week, compared to 3 articles on an average week.

Search Interest

Only 4 people have searched for ANIX on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.

MarketBeat Follows

11 people have added Anixa Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 83% compared to the previous 30 days.

Company Ownership

• Score: 4.6 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

4 insiders have purchased shares of Anixa Biosciences in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $319,120.00 in company stock, which represents 0.3166% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Anixa Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $319,120.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

26.40% of the stock of Anixa Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

29.13% of the stock of Anixa Biosciences is held by institutions.

Company Calendar

• Last Earnings: 9/09/2026
• Today: 10/10/2026
• Fiscal Year End: 10/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ANIX
• CIK: 715446
• Web: www.anixa.com
• Phone: (408) 708-9808
• Fax: 631-549-5974
• Employees: 4
• Year Founded: 1982

Price Target and Rating

• Average Price Target for Anixa Biosciences: $8.00
• High Price Target: $10.00
• Low Price Target: $6.00
• Potential Upside/Downside: +175.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.40
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.32)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$10.93 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -76.59%
• Return on Assets: -67.80%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.55
• Quick Ratio: 8.54

Sales & Book Value

• Annual Sales: $210 thousand
• Price / Sales: 480.02
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.42 per share
• Price / Book: 6.90

Miscellaneous

• Outstanding Shares: 34,760,000
• Free Float: 25,586,000
• Market Cap: $100.80 million
• Optionable: Optionable
• Beta: 0.47